Teva, Sanofi say drug to treat IBD met primary targets
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals.
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS
The FDA bestows a Breakthrough Therapy designation to Sanofi's tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis.
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave early next year.
Sanofi to invest $1 bln in insulin production site in Beijing, local authority says
French drugmaker Sanofi plans to invest 1 billion euros ($1.05 billion) to build a new insulin production base in Beijing, a local authority in the city said on Monday, citing a memorandum of understanding the company signed with an economic zone.
Pharma giant Sanofi opens $595 million vaccine facility in Singapore to boost preparedness for potential pandemics
The facility, known as Modulus, can switch between making different vaccines or treatments in a matter of days. It will contribute about 200 skilled jobs to Singapore, and will be fully operational by mid-2026.
Sanofi plans to change hospital drug-discount program, WSJ reports
French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income and uninsured patients, the Wall Street Journal reported on Friday.
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse drug portfolio and a robust pipeline of future drugs to market, this big pharma brand will play a major role in treatments in the next decades to come. The stock currently offers a 4% dividend yield, while trading below its moving average and with a mixed valuation picture vs key peers.
SandboxAQ CEO on the firm's partnership with Sanofi
Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical development.
Why Sanofi Stock Flew Higher on Friday
No investor can ignore a crushing bottom-line beat and raised profitability guidance.
